---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027200"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2026-06-04T12:00:39+00:00"
generated_at: "2026-06-04T12:06:35.794541+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma signs term sheet to acquire CL-741, a Phase 1-ready c-MET inhibitor; outlines 2026 milestones

## Summary
- Acquiring worldwide rights to CL-741, an oral type IIb c-MET kinase inhibitor targeting EGFR-mutated lung cancer and esophageal/gastric cancers.
- CL-741 is Phase 1-ready; Phase 1 study initiation planned for H2 2026.
- ENV-105 Phase 2 trial in prostate cancer continues; more trial sites expected by year-end.
- ENV-105 Phase 1 in NSCLC results anticipated by Q3 2026.
- Over $8M in non-dilutive funding; low monthly burn rate highlighted.

## SEC filing metadata
- accession: 0001493152-26-027200
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2026-06-04T12:00:39+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315226027200/0001493152-26-027200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315226027200/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027200
- JSON: https://secwatch.observer/filing/0001493152-26-027200.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027200.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.